Your Patients Need Their Injections — Here's How to Help

When a patient with wet AMD or macular edema walks into your office expecting their Byooviz (Ranibizumab-nuna) injection and you don't have it in stock, the clinical stakes are real. Treatment delays in anti-VEGF therapy can lead to irreversible vision loss, and patients depend on their providers to keep therapy on track.

This guide outlines practical steps your practice can take to help patients access Byooviz — or appropriate alternatives — when supply is constrained.

Current Byooviz Availability

As of early 2026, Byooviz is not on the FDA's formal drug shortage list, but availability remains inconsistent across practices and regions. Key factors driving this variability include:

• Practice-level formulary decisions: Not all retinal practices have added Byooviz to their formulary, particularly as the broader Ranibizumab market segment (including Lucentis) has contracted
• Buy-and-bill economics: ASP-based reimbursement for biosimilars may not provide sufficient margin for some practices, especially smaller clinics
• Specialty distribution constraints: Byooviz is distributed through specialty channels, and ordering logistics differ from traditional wholesale purchasing
• Competition from newer agents: Vabysmo (Faricimab) and Eylea HD (Aflibercept 8 mg) have captured significant market share, further reducing demand for Ranibizumab products

For a comprehensive market overview, see our provider briefing on the Byooviz shortage.

Why Patients Can't Find Byooviz

From the patient's perspective, the problem often looks like a shortage even when it's really a stocking issue. Common scenarios include:

• Their retinal specialist doesn't carry Byooviz and hasn't established a distribution relationship
• Their insurance approved Byooviz specifically (perhaps through interchangeability substitution for Lucentis), but their provider stocks a different anti-VEGF
• Prior authorization delays create gaps between when the drug is approved and when it can be administered
• The patient relocated or switched providers and their new ophthalmologist uses a different formulary

Understanding these patient-facing barriers can help your practice anticipate needs and develop solutions proactively.

What Providers Can Do: 5 Practical Steps

Step 1: Establish a Reliable Ordering Relationship

If your practice treats patients who need Ranibizumab and you don't currently stock Byooviz, consider establishing a relationship with a specialty distributor. Biogen Biosimilar Support Services (1-877-422-8360) can help onboard your practice, including setting up ordering channels and providing volume-based pricing information.

Even if you don't plan to stock Byooviz routinely, having an ordering pathway established means you can get it quickly when a patient needs it.

Step 2: Direct Patients to Medfinder

When your practice can't supply Byooviz, Medfinder is a valuable tool to recommend to patients. It helps them find providers and specialty pharmacies that have Byooviz in stock in their area. Rather than asking patients to call around blindly, you can give them a specific resource.

Consider adding Medfinder to your patient-facing materials for situations when any specialty medication is temporarily unavailable.

Step 3: Streamline Prior Authorization Workflows

Insurance-related delays are one of the most common barriers to Byooviz access. To minimize these:

• Initiate prior authorization as early as possible — ideally at the time of diagnosis or treatment planning, not at the injection visit
• Use the HCPCS Q-code Q5124 for Byooviz billing
• Leverage Biogen's prior authorization support team for complex cases
• Document medical necessity thoroughly, including treatment history and previous anti-VEGF use
• For Medicare Advantage patients, be aware that step therapy requirements (e.g., trying Avastin first) may delay Byooviz access

Step 4: Develop a Therapeutic Substitution Protocol

Having a documented protocol for when Byooviz (or any anti-VEGF agent) is unavailable protects both your patients and your practice:

• Identify acceptable substitutions based on indication and patient history
• Establish dosing equivalency references for switching between agents
• Define when to use Cimerli (same molecule, interchangeable) vs. switching to Eylea or Vabysmo
• Communicate the protocol to your scheduling and clinical teams so patients aren't turned away when a specific drug is unavailable

The key principle: no patient should miss an injection because of a stocking issue. Therapeutic alternatives should be readily available.

Step 5: Communicate Proactively With Patients

Many patients don't understand why a prescribed medication isn't available or how the buy-and-bill model works. Clear, proactive communication can reduce anxiety and improve compliance:

• When prescribing Byooviz, explain that it may need to be special-ordered and discuss timing
• If you plan to substitute another anti-VEGF agent, explain why and reassure patients about clinical equivalence
• Provide written materials about Byooviz alternatives and savings programs
• Share resources like Medfinder and the Biogen support line

Anti-VEGF Alternatives for Your Practice

When Byooviz isn't available, these alternatives provide clinically effective options:

• Cimerli (Ranibizumab-eqrn): Interchangeable Lucentis biosimilar. Approved for all five Lucentis indications, including DME and DR (at 0.3 mg dose). The most seamless substitution for Byooviz.
• Lucentis (Ranibizumab): Reference product. Higher cost (~$1,850/vial) but identical molecule.
• Eylea (Aflibercept 2 mg): Most widely used anti-VEGF. Approved for wet AMD, DME, DR, and RVO. 4-8 week dosing.
• Eylea HD (Aflibercept 8 mg): Extended dosing intervals (8-16 weeks). Approved for wet AMD and DME.
• Vabysmo (Faricimab): Bispecific antibody targeting VEGF-A and Ang-2. Intervals up to 16 weeks. Approved for wet AMD and DME.
• Avastin (Bevacizumab): Off-label, compounded. ~$50-$75/dose. Often first-line for cost-sensitive patients and step therapy requirements.

Workflow Tips for Managing Anti-VEGF Availability

• Maintain a multi-product formulary: Stocking at least two anti-VEGF options ensures you always have a backup when one product is unavailable
• Track inventory levels weekly: Implement par-level monitoring with automatic reorder triggers for anti-VEGF products
• Coordinate with scheduling: When a product is low, alert schedulers so they can flag upcoming appointments that may be affected
• Build distributor relationships: Having accounts with multiple specialty distributors provides redundancy in your supply chain
• Stay current on reimbursement: Monitor quarterly ASP updates for Byooviz (Q5124) to ensure favorable buy-and-bill margins

Final Thoughts

Helping patients access Byooviz in 2026 requires a combination of proactive supply chain management, insurance navigation, patient communication, and clinical flexibility. The anti-VEGF market is more competitive and complex than ever, but the fundamentals haven't changed: consistent, timely treatment is what protects patient vision.

By establishing reliable ordering pathways, leveraging tools like Medfinder, and maintaining a documented substitution protocol, your practice can minimize the impact of Byooviz availability challenges on patient outcomes.

For additional provider resources, see our guide to helping patients save money on Byooviz.